Federal Register / Vol. 65, No. 115 / Wednesday, June 14, 2000 / Notices 37391

present their views on the issues raised in the

interim reports. There also will be an

opportunity for comments from the audience.

The July hearing is the first of a series of joint

public hearings to be conducted in several

regions of the country through the fall of

2000 to solicit testimony on the reports.

Information from the hearings will be

incorporated as definitive statements in the

final reports expected to be completed in

early 2001.

Persons who would like to make a brief

oral comment (3–5 minutes) during the July

hearing will be placed on the agenda as time

permits. To be included on the agenda,

please submit testimony by June 26, 2000, to

Patrice Upchurch at (301) 458–4540, by email at pupchurch@cdc.gov, or postal

address at NCHS, Presidential Building,

Room 1100, 6525 Belcrest Road, Hyattsville,

Maryland 20782. Persons wishing to submit

written testimony only (no more than 2–3

typewritten pages) should also adhere to the

due date of June 26, 2000. Please consult Ms.

Upchurch for further information about these

arrangements. Additional information about

the meeting will be provided on the NCVHS

homepage at http://www.ncvhs.hhs.gov/

shortly before the meeting date. All

participants are encouraged to review the

interim reports before the meeting.

For Further Information Contact:

Substantive program information as well as

summaries of meetings and a roster of

committee members may be obtained from

Ms. Upchurch at the address above; or

Marjorie S. Greenberg, Executive Secretary,

NCVHS, National Center for Health Statistics,

Centers for Disease Control and Prevention,

Room 1100, Presidential Building, 6525

Belcrest Road, Hyattsville, Maryland 20782,

telephone (301) 458–4245. Information also

is available on the NCVHS home page of the

HHS website: http://www.ncvhs.hhs.gov/

where an agenda for the meeting will be

posted when available.

Dated: June 7, 2000.

James Scanlon,

Director, Division of Data Policy, Office of

the Assistant Secretary for Planning and

Evaluation.

[FR Doc. 00–14985 Filed 6–13–00; 8:45 am]

BILLING CODE 4151–05–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

[Program Announcement 00126]

Neurodevelopmental Test Methods

Research; Notice of Availability of

Funds

A. Purpose

The Agency for Toxic Substances and

Disease Registry (ATSDR) announces

the availability of fiscal year (FY) 2000

funds for a grant program for

Neurodevelopmental Test Methods

Research. This program addresses the

‘‘Healthy People 2010’’ focus area of

Environmental Health. For the

conference copy of the ‘‘Healthy People

2010.’’ visit the internet site: http://

www.health.gov/healthypeople.

The purpose of the program is to

determine and validate a battery of

neurodevelomental tests for use in

assessing the effects of prenatal or

postnatal exposure to developmental

toxicants. The battery of tests should: (1)

be applicable to a wide range of

potential neurodevelopmental toxicants

found at waste sites and in the

environment including metals and

solvents; (2) be applicable to a wide

range of exposure levels found in the

environment; and (3) cover a broad

range of developmental domains

including cognitive function, sensory

function, motor function, and complex

multi-tasking performance. These

research methods will address an

agency goal to develop methods and

tools for evaluating human health

consequences from exposure to toxic

substances in the environment.

B. Eligible Applicants

Applications may be submitted by

official public health agencies of the

States, or their bona fide agents. This

includes the District of Columbia,

American Samoa, the Commonwealth of

Puerto Rico, the Virgin Islands, the

Federated States of Micronesia, Guam,

the Northern Mariana Islands, the

Republic of the Marshall Island, the

Republic of Palau, federally-recognized

Indian tribal governments, public and

private non-profit and for profit

universities, colleges, and research

institutions.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $100,000 is available

in Fiscal Year 2000 to fund one award.

It is expected to begin on or about

September 30, 2000, and will be made

for a 12-month budget period within a

project period of up to 3 years. Funding

estimates may change.

Continuation awards within the

project period will be made on the basis

of satisfactory progress as evidenced by

required reports and the availability of

funds.

Use of Funds

Funds may be expended for

reasonable program purposes, such as

personnel, travel, supplies and services.

Funds for contractual services may be

requested; however, the grantee, as the

direct and primary recipient of ATSDR

grant funds, must perform a substantive

role in carrying out project activities

and not merely serve as a conduit for an

award to another party or provide funds

to an ineligible party. Equipment may

be purchased with grant funds.

However, the equipment proposed

should be appropriate and reasonable

for the research activity to be

conducted. Property may be acquired

only when authorized in the grant. The

grantee, as part of the application

process, should provide a justification

of need to acquire property, the

description, and the cost of purchase

versus lease.

D. Program Requirements

Applicant will conduct studies to

develop and validate a battery of

neurodevelopmental tests for use in

assessing the effects of prenatal or

postnatal exposure to developmental

neurotoxicants. Investigations of

adverse health effects in developing

organisms that are attributable to

neurotoxicant exposure require

measures that are sensitive across a

wide range of exposure levels.

The study should include children at

risk for the kinds of performance

deficits these tests endeavor to measure,

e.g., low birth weight children (<1000

grams), and/or children diagnosed as

learning-disabled. Such a study will

determine the ability of these tests and

procedures to identify analogous

deficits hypothesized to arise from

developmental exposure to

methylmercury and other

neurotoxicants. Those components of

the test battery that demonstrate

validity, i.e., prove successful at

differentiating these children from a

referent group of children, will then be

incorporated into future studies of

possible developmental neurotoxicants.

Applicants should have primary access

to data in children which can be used

to facilitate the validation step.

The applicant will establish an ad hoc

advisory group for the study. A major

purpose of the group will be to provide

advice on developing and distributing

educational materials on the use and

application of this test battery to a broad

spectrum of health professionals.

E. Application Content

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections to develop

the application content. Your

application will be evaluated on the

criteria listed, so it is important to

37392 Federal Register / Vol. 65, No. 115 / Wednesday, June 14, 2000 / Notices

follow them in laying out your program

plan. The narrative should be doublespaced pages, printed on one side, with

one inch margin, and unreduced font.

F. Submission and Deadline

Submit the original and five copies of

the application PHS Form 398 (OMB

Number 0925–0001). Forms are

available at the following Internet

address: www.cdc.gov/od/pgo/

forminfo.htm or in the application kit.

On or before July 15, 2000, submit the

application to the Grants Management

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

Deadline: Applications shall be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicant

must request a legibly-dated U.S. Postal

Service postmark or obtain a legiblydated receipt from a commercial carrier

or U.S. Postal Service). Private metered

postmarks shall not be acceptable as

proof of timely mailing.

Late Applications: Applications

which do not meet the criteria in (a) or

(b) above are considered late

applications, will not be considered,

and will be returned to the applicant.

G. Evaluation Criteria

The application will be evaluated

against the following criteria by an

independent review group appointed by

ATSDR.

Proposed Program—60 Percent of Total

The extent to which the applicant’s

application addresses:

1. The scientific merit of the

hypothesis of the proposed project,

including the originality of the approach

and the feasibility, adequacy, and

rationale of the design (the design of the

study should ensure statistical validity

for comparison with other research

projects); (15 percent)

2. The technical merit of the methods

and procedures for the proposed project,

including the degree to which the

project can be expected to yield results

that meet the program objective as

described in the PURPOSE section of

this announcement; and demonstrate

that an advisory group can be

established at the onset of the project;

(25 percent)

3. The proposed project schedule,

including clearly established and

obtainable project objectives for which

progress toward attainment can and will

be measured and plans for publishing

research results in peer reviewed

journals; (15 percent) and

4. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research (5 percent).

This includes:

a. The proposed plan for the inclusion

of both sexes and racial and ethnic

minority populations for appropriate

representation.

b. The proposed justification when

representation is limited or absent.

c. A statement as to whether the

design of the study is adequate to

measure differences when warranted.

d. A statement as to whether the plans

for recruitment and outreach for study

participants include the process of

establishing partnerships with

community(ies) and recognition of

mutual benefits.

Program Personnel—30 Percent of Total

The extent to which the application

has described:

(1) The qualifications, experience, and

commitment of the Principal

Investigator, and his/her ability to

devote adequate time and effort to

provide effective leadership; and

(2) The competence of associate

investigators to accomplish the

proposed study, their commitment, and

time devoted to the study.

Institutional Resources and

Commitment—10 Percent of Total

Description of the adequacy and

commitment of the institutional

resources to administer the program and

the adequacy of the facilities as they

impact on performance of the proposed

study.

Program Budget—(NOT SCORED)

The extent to which the budget is

reasonable, clearly justified, and

consistent with intended use of funds.

Human Subjects—(NOT SCORED)

Does the application adequately

address the requirements of 45 CFR part

46 for the protection of human subjects?

H. Other Requirements

Technical Reporting Requirements

Provide CDC with the original plus

two copies of

1. An annual progress report

2. Financial status report, no more

than 90 days after the end of the budget

period

3. Final financial report and

performance report, no more than 90

days after the end of the project period

Send all reports to Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

For description of the following Other

Requirements, see Attachment I.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–17 Peer and Technical Reviews of

Final Reports of Health Studies—

ATSDR

AR–18 Cost Recovery-ATSDR

AR–19 Third Party Agreements—

ATSDR

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

Section 104(i)(5)and(14) of the

Comprehensive Environmental

Response, Compensation, and Liability

Act of 1980 (CERCLA), as amended, 42

U.S.C. 9604 by the Superfund

Amendments and Reauthorization Act

(SARA) of 1986. The Catalog of Federal

Domestic Assistance number is 93.161.

J. Where to Obtain Additional

Information

This and other CDC/ATSDR

announcements can be found on the

CDC home page, Internet Address-http:/

/www.cdc.gov. Click on ‘‘Funding’’ then

‘‘Grants and Cooperative Agreements.’’

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888–472–6874). You will be asked to

leave your name and address and will

be instructed to identify the

Announcement number of interest

(00126).

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Nelda

Godfrey, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

Room 3000, 2920 Brandywine Road,

Atlanta, Georgia 30341–4146,

Telephone number (770)488–2722,

Email address:NAG9@CDC.GOV.

For program technical assistance,

contact: Dr. Mildred Williams-Johnson,

Project Officer, Division of Toxicology,

Agency for Toxic Substances and

Disease Registry, 1600 Clifton Road, NE,

Mailstop E–29, Atlanta, Georgia 30333,

Telephone number: (404) 639–6306, Email address: MMW1@CDC.GOV.

Federal Register / Vol. 65, No. 115 / Wednesday, June 14, 2000 / Notices 37393

Dated: June 8, 2000.

Georgi Jones,

Director, Office of Policy and External Affairs,

Agency for Toxic Substances and Disease

Registry.

[FR Doc. 00–14941 Filed 6–13–00; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

[ATSDR–158]

Public Health Assessments Completed

AGENCY: Agency for Toxic Substances

and Disease Registry (ATSDR),

Department of Health and Human

Services (HHS).

ACTION: Notice.

SUMMARY: This notice announces those

sites for which ATSDR has completed

public health assessments during the

period from January through March

2000. This list includes sites that are on

or proposed for inclusion on the

National Priorities List (NPL), and

includes sites for which assessments

were prepared in response to requests

from the public.

FOR FURTHER INFORMATION CONTACT:

Robert C. Williams, P.E., DEE, Assistant

Surgeon General, Director, Division of

Health Assessment and Consultation,

Agency for Toxic Substances and

Disease Registry, 1600 Clifton Road,

NE., Mailstop E–32, Atlanta, Georgia

30333, telephone (404) 639–0610.

SUPPLEMENTARY INFORMATION: The most

recent list of completed public health

assessments was published in the

Federal Register on March 21, 2000 (65

FR15163). This announcement is the

responsibility of ATSDR under the

regulation, Public Health Assessments

and Health Effects Studies of Hazardous

Substances Releases and Facilities (42

CFR part 90). This rule sets forth

ATSDR’s procedures for the conduct of

public health assessments under section

104(i) of the Comprehensive

Environmental Response,

Compensation, and Liability Act

(CERCLA), as amended by the

Superfund Amendments and

Reauthorization Act (SARA) (42 U.S.C.

9604(i)).

Availability

The completed public health

assessments and addenda are available

for public inspection at the Division of

Health Assessment and Consultation,

Agency for Toxic Substances and

Disease Registry, Building 33, Executive

Park Drive, Atlanta, Georgia (not a

mailing address), between 8 a.m. and

4:30 p.m., Monday through Friday

except legal holidays. The completed

public health assessments are also

available by mail through the U.S.

Department of Commerce, National

Technical Information Service (NTIS),

5285 Port Royal Road, Springfield,

Virginia 22161, or by telephone at (703)

605–6000. NTIS charges for copies of

public health assessments and addenda.

The NTIS order numbers are listed in

parentheses following the site names.

Public Health Assesssments Completed

or Issued

Between January 1 and March 31,

2000 public health assessments were

issued for the sites listed below:

NPL Sites

Arizona

Klondyke Tailings (a/k/a Aravaipa

Creek Mine Tailings)—Klondyke—

(PB20–103287)

Tucson International Airport Area (a/k/

a ElVado Residential Properties)—

Tucson—(PB20–104079)

Colorado

Air Force Plant PJKS—Wateron—

(PB20–105008)

Connecticut

Upjohn Co-Fine Chemicals Division—

North Haven—(PB20–104239)

Illinois

Indian Refinery-Texaco Lawrenceville

(a/k/a Texaco

Incorporated Lawrenceville Refinery)—

Lawrenceville—(PB20–105551)

Parsons Casket Hardware Company—

Belvidere—(PB20–103235)

Indiana

Vickers Warehouse Site—Anderson—

(PB20–103286)

Kansas

Fort Riley (a/k/a Fort Riley Military

Reservation)—Fort Riley—(PB20–

104840)

Michigan

Lafarge Corporation-Alpena Plant—

Alpena—(PB20–104078)

New York

Seneca Army Depot—Romulus—(PB20–

104790)

Pennsylvania

Callery Chemical Company—Evans

City—(PB20–104502)

Tennessee

Jersey Miniere Zinc Company (a/k/a

Pasminco Clarksville Zinc Plant)—

Clarksville—(PB20–104503)

Texas

City of Perryton Well No.2 (a/k/a

Perryton Water Well Number 2)—

Perryton—(PB20–103408)

Many Diversified Interests,

Incorporated—Houston—(PB20–

104791)

Non NPL Petitioned Sites

Massachusetts

Morse Cutting Tools—New Bedford—

(PB20–105552)

Rock Avenue 21–E Dump (a/k/a Rock

Avenue 21–E–Dump Site)—

Winchester—(PB20–100632)

Dated: June 8, 2000.

Georgi Jones,

Director, Office of Policy and External Affairs,

Agency for Toxic Substances and Disease

Registry.

[FR Doc. 00–14940 Filed 6–13–00; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention (CDC)

CDC, Advisory Committee on HIV and

STD Prevention: Notice of Charter

Renewal

This gives notice under the Federal

Advisory Committee Act (Public Law

92–463) of October 6, 1972, that the

CDC, Advisory Committee on HIV and

STD Prevention of the Centers for

Disease Control and Prevention, of the

Department of Health and Human

Services, has been renewed for a 2-year

period beginning May 11, 2000, through

May 11, 2002.

For further information, contact Ron

Valdiserri, M.D., Executive Secretary,

CDC, Advisory Committee on HIV and

STD Prevention, 1600 Clifton Road, NE,

m/s E–07, Atlanta, Georgia 30333.

Telephone 404/639–8002, or fax 404/

639–8600.

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.